{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T06:27:57Z","timestamp":1787120877538,"version":"build-2736575974"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Colorectal cancer (CRC) with human epidermal growth factor receptor 2 (HER2) overexpression and RAS mutations is often associated with poor response to conventional treatments, presenting substantial therapeutic challenges. This report describes a remarkable response in a patient with HER2-amplified, KRAS-mutated metastatic rectal cancer, who was treated with a zanidatamab-based combination regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 54-year-old male was admitted to our hospital complaining of hematochezia and was diagnosed with rectal adenocarcinoma via biopsy. Baseline imaging revealed extensive, unresectable liver metastases. Next-generation sequencing identified a KRAS G12D mutation alongside HER2 amplification. Although the combination of chemotherapy and bevacizumab yielded promising efficacy, but tumor markers still remained high. When the anti-HER2 bispecific antibody zanidatamab was added, after three cycles of this triplet therapy, the liver metastases exhibited radiographic regression, and tumor markers showed substantial decline. The patient achieved sufficient downstaging and subsequently underwent successful hepatic resection. Pathological examination confirmed negative surgical margins.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case underscores the potential of HER2 inhibition as an effective therapeutic strategy in KRAS-mutated CRC. It also highlights zanidatamab\u2019s promise as part of a conversion therapy approach in patients with historically refractory disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1925363","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:48:05Z","timestamp":1787118485000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Unlocking HER2 as a target in KRAS-mutated rectal cancer: a case of significant response to zanidatamab-based regimen"],"prefix":"10.3389","volume":"17","author":[{"given":"Kexun","family":"Zhou","sequence":"first","affiliation":[{"name":"Division of Abdominal Cancer, Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Abdominal Cancer, Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/path.4679","article-title":"HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials","volume":"238","author":"Richman","year":"2016","journal-title":"J Pathol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"11432","DOI":"10.1038\/s41598-024-62096-x","article-title":"RAS\/RAF mutations and microsatellite instability status in primary colorectal cancers according to HER2 amplification","volume":"14","author":"Lee","year":"2024","journal-title":"Sci Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.s297596","article-title":"HER2 overexpression and mismatch repair deficiency are correlated with Malignancy in colorectal cancer","volume":"13","author":"Luo","year":"2021","journal-title":"Cancer Manag Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad200","article-title":"Impact of anti-EGFR therapies on HER2-positive metastatic colorectal cancer: a systematic literature review and meta-analysis of clinical outcomes","volume":"28","author":"Bekaii-Saab","year":"2023","journal-title":"Oncologist"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30904-5","article-title":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study","volume":"20","author":"Meric-Bernstam","year":"2019","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2517729","article-title":"Zanidatamab with and without Tislelizumab in HER2-positive gastroesophageal cancer","volume":"394","author":"Shitara","year":"2026","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1339302","article-title":"ERBB2 (HER2) amplifications and co-occurring KRAS alterations in the circulating cell-free DNA of pancreatic ductal adenocarcinoma patients and response to HER2 inhibition","volume":"14","author":"Barzi","year":"2024","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.22034\/APJCP.2017.18.8.2209","article-title":"BRAF, KRAS and PIK3CA mutation and sensitivity to trastuzumab in breast cancer cell line model","volume":"18","author":"Patra","year":"2017","journal-title":"Asian Pac J Cancer Prev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-03966-7","article-title":"KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer","volume":"149","author":"Shimozaki","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s44276-025-00148-z","article-title":"Association of HER2 amplification or overexpression with overall survival in advanced upper gastrointestinal adenocarcinomas","volume":"3","author":"Pan","year":"2025","journal-title":"BJC Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000911","article-title":"Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial","volume":"5","author":"Sartore-Bianchi","year":"2020","journal-title":"ESMO Open"},{"key":"B15","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer (Version 1. 2026)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068022","article-title":"Colorectal cancer patients with low abundance of KRAS mutation may benefit from EGFR antibody therapy","volume":"8","author":"Yu","year":"2013","journal-title":"PloS One"},{"key":"B17","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1093\/annonc\/mdz082","article-title":"Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial","volume":"30","author":"Santos","year":"2019","journal-title":"Ann Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02626","article-title":"Trastuzumab deruxtecan in advanced solid tumors with human epidermal growth factor receptor 2 amplification identified by plasma cell-free DNA testing: a multicenter, single-arm, phase II basket trial","volume":"42","author":"Yagisawa","year":"2024","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/s41467-023-37029-3","article-title":"An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity","volume":"14","author":"Weisser","year":"2023","journal-title":"Nat Commun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-23-0838","article-title":"Co-clinical trial of novel bispecific anti-HER2 antibody zanidatamab in patient-derived xenografts","volume":"14","author":"DiPeri","year":"2024","journal-title":"Cancer Discov"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00621-0","article-title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study","volume":"23","author":"Meric-Bernstam","year":"2022","journal-title":"Lancet Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.1320","article-title":"746P A 2-year follow-up of zanidatamab (Zani) + mFOLFOX6 \u00b1 bevacizumab (Bev) in first-line (1L) treatment of patients (Pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced\/metastatic colorectal cancer (mCRC)","volume":"36","author":"Rha","year":"2025","journal-title":"Ann Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"S224","DOI":"10.1016\/j.annonc.2021.05.018","article-title":"O-14 Exploratory biomarker analysis of trastuzumab deruxtecan in DESTINY-Gastric01, a randomized, phase 2, multicenter, open-label study in patients with HER2-positive or -low advanced gastric or gastroesophageal junction adenocarcinoma","volume":"32","author":"Shitara","year":"2021","journal-title":"Ann Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1925363\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:48:07Z","timestamp":1787118487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1925363\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":23,"alternative-id":["10.3389\/fimmu.2026.1925363"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1925363","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"article-number":"1925363"}}